

Michael J. FitzGerald\*  
Eoin L. Kreditor\*  
Eric P. Francisconi  
Lynne Bolduc  
George Vausher, LLM, CPA‡  
Eric D. Dean  
John C. Clough  
David M. Lawrence  
Natalie N. FitzGerald  
David A. Kelly  
Jodi M. Wirth  
Brook J. Changala  
John M. Marston†  
Deborah M. Rosenthal†  
Maria M. Rullo†  
Jeanine A. Scalero †  
Larry S. Zeman†

March 22, 2019

OTC Markets Group Inc.  
304 Hudson Street, 3<sup>rd</sup> Floor  
New York, NY 10013

This law firm has been retained as general counsel to AmeraMex International, Inc., a Nevada corporation, with its principal office in Chico, California (the “Issuer”), which issues securities quoted on the OTC Pink Sheets (the “Securities”). As counsel to the Issuer, we have been requested to provide a letter with respect to the information publicly disclosed by the Issuer and published through the OTC Disclosure & News Service. Specifically, we have been asked to determine whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933 (the “Act”).

I am a U.S. resident and I am licensed to practice law in the State of California. This opinion is limited to the laws of the United States of America. I am permitted to practice before the Securities and Exchange Commission (“SEC”) and have not, at any time, been prohibited from practice thereunder. I do not beneficially own any shares of the Issuer’s securities and there is no agreement between me and the Issuer to receive in the future, shares of the Issuer’s stock, in payment for services.

I am not currently, nor have I been in the past five years, been suspended or barred from practicing in any state or jurisdiction and have not been charged in a civil or criminal case.

I have examined the corporate records and other documents and such questions of law as I considered necessary or appropriate for purposes of rendering the letter. The documents (the “Information”) that I have reviewed include, but are not limited to:

- a) The Issuer’s shareholder list dated March 15, 2019;
- b) The Issuer’s Amended Annual Report for the period ending December 31, 2018 and published on the OTC Markets website on March 20, 2019; and
- c) The Issuer’s financial statements (the Balance Sheet, Statement of Cash Flow, and Statement of Operations) for the year 2018 published on the OTC Markets website on March 18, 2019.

In examining the Documents, I have assumed that:

1. All statements and representations contained therein were accurate and truthful;

March 22, 2019

Page 2

2. All signatures contained therein were genuine;
3. All documents submitted to me as originals were true and completed;
4. All copies submitted to me were true and accurate copies; and
5. All natural persons who signed documents had the legal capacity to do so.

I have also relied upon certain matters of fact contained in public information, disseminated by public officials and obtained from officers of the Issuer. After reasonable investigation, I believe these sources for such information to be reliable and truthful.

The Issuer posted its Annual Report for the year ending December 31, 2018 to the OTC Disclosure & News Service on March 20, 2019, along with all required exhibits and financial statements for the periods in question (collectively, "Information"). I have reviewed the Information published by the Issuer on the OTC Disclosure & News Service and, after reasonable investigation, it is my opinion that the Information constitutes "adequate current public information" concerning the Issuer's securities and "is available" within the meaning of Rule 144(c)(2) under the Act. It is my further opinion that the Information includes all of the information that a broker-dealer would be required to obtain for the Issuer's securities under Rule 15c2-11 of the Securities Exchange Act of 1934. It is my opinion that such Information complies as to form with the OTC Markets Group's Guidelines Pink Basic Disclosure Guidelines, which are located on the internet at [www.otcmarkets.com](http://www.otcmarkets.com). Finally, the Information has been posted through the OTC Disclosure & News Service.

The person responsible for the preparation of the unaudited financial statements contained in the Information was the President of the Issuer, Lee Hamre, assisted by Hope Stone, Chief Financial Officer. The Issuer's transfer agent is Pacific Stock Transfer Co., which is registered with the SEC. I relied upon information provided by the transfer agent and reviews of the lists by Mr. Hamre, Ms. Stone, and other officers and agents of the Issuer to confirm the number of outstanding shares set forth in the Information.

I have met personally with a majority of the Directors and management (Marty Tullio and Lee Hamre) of the Issuer with whom I discussed the Information, as amended and published by the Issuer through the OTC Disclosure & News Service. To the best of my knowledge, after inquiry of management and the Directors of the Issuer, neither the Issuer of the Securities, any 5% holder of such securities, nor counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

OTC Markets Group is entitled to rely upon this letter in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Act. No person other than OTC Markets Group is entitled to rely on the information in this letter.


No person other than OTC Markets Group is entitled to rely upon this letter and I hereby grant OTC Markets Group full and complete permission and rights to publish the letter through the OTC Disclosure & News Service for viewing by the public and regulators.

March 22, 2019  
Page 3

The predecessor to the Issuer was a “shell company” as defined in Rules 405 of the Act and 12b-2 of the Exchange Act of 1934.

Very truly yours,

FitzGerald Yap Kreditor, LLP



Lynne Bolduc, Esq.

cc: Lee Hamre, President of AmeraMex International, Inc.